Third-line therapies in patients with Kawasaki disease refractory to first-and second-line intravenous immunoglobulin therapy  

作　　者：Takashi Furuta Hiroki Yasudo Seigo Okada Yuji Ohnishi Akiko Kawakami-Miyake Yasuo Suzuki Shouichi Ohga Shunji Hasegawa 

机构地区：[1]Department of Pediatrics,Yamaguchi University Graduate School of Medicine,1-1-1 Minamikogushi,Ube,Yamaguchi,755-8505,Japan [2]Department of Pediatrics,Graduate School of Medical Sciences,Kyushu University,3-1-1 Maidashi,Higashi-ku,Fukuoka,812-8582,Japan

出　　处：《World Journal of Pediatrics》2022年第11期781-785,共5页世界儿科杂志（英文版）

基　　金：This work was supported in part by Japan Society for the Promotion of Science(JSPS)KAKENHI[Nos.16K19647(SY),19K08323(SH),and 21K15906(OS)]from the Ministry of Education,Culture,Sports,Science and Technology.

摘　　要：Kawasaki disease(KD)is an acute febrile ilness characterized by systemic vasculitis affecting the small-and mediumsized arteries in children [1,2].One of the most critical complications of KD is the development of coronary artery lesions(CALs)approximately after 12 days of ilness,which may lead to myocardial infarction[3].High-dose intravenous immunoglobulin(IVIG)and oral administration of aspirin have been established as the first-line therapy for KD[4,5].

关 键 词：INTRAVENOUS acute IMMUNOGLOBULIN 

分 类 号：R725.4[医药卫生—儿科] R726.9[医药卫生—临床医学]